Status: Not yet recruiting
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
This is a prospective, open-label, multi-center, single-arm clinical trial
Participants needed: 45
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang Cancer HospitalUpdated: Jan 15, 2026Locations: 1
Eligibility criteria
Age ≥ 18 and ≤ 75 years at the time of signing the informed consent form (ICF),... [+7]
Tumor histology or cytology confirms combined small cell lung cancer (SCLC), neu... [+11]